Kamiren (Doxazosin)

Doxazosin, the active ingredient in Kamiren, is an alpha-1 adrenergic blocker presented as an oral tablet for oral use. It lowers blood pressure in patients with hypertension and eases urinary symptoms in men with benign prostatic hyperplasia. GNH USA supplies Kamiren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the alpha‑1 adrenergic receptor pathway to manage vascular and prostatic conditions.

Hypertension: reduces peripheral vascular resistance and lowers systolic and diastolic blood pressure. Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing retention.

Doxazosin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or weakness. - Nasal congestion or runny nose. - Peripheral edema. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Marked hypotension or syncope. - Priapism (prolonged erection). - Severe allergic reaction, including rash, itching, or swelling. - Angioedema involving face, lips, or throat. - Liver function abnormalities. - Cardiac arrhythmias in susceptible individuals.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely.

Monitor blood pressure: assess for orthostatic changes after the first dose. Assess renal and hepatic function: dose adjustments may be needed in impairment. Review cardiovascular history: caution in patients with recent myocardial infarction or severe heart failure. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Use with caution in elderly patients prone to falls. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other antihypertensives (e.g., beta‑blockers, other alpha‑blockers): additive hypotensive effect. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase doxazosin plasma levels. - Lithium: may enhance lithium toxicity. - Diuretics used concurrently: heightened risk of orthostatic hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce doxazosin exposure. - Calcium channel blockers (e.g., amlodipine): may increase blood pressure‑lowering effect. - ACE inhibitors or ARBs: monitor for excessive blood pressure drop. - Antidiabetic agents: possible need for dose adjustment of glucose‑lowering drugs.